How one molecule made the impossible pill possible

"Peptides cannot be taken as pills" was treated as a law of biology for fifty years. Stomach acid and digestive enzymes shred them in seconds, and the gut wall blocks anything that survives. That law broke in 2019 with Rybelsus, the oral form of semaglutide, and the molecule that broke it is not the drug itself. It is a permeation enhancer called Salcaprozate Sodium, or SNAC.

Four steps, all in your stomach

Based on the Buckley et al. 2018 mechanism characterization, SNAC works by creating a transient, localized microenvironment in the stomach that protects the peptide and lets it cross the gastric epithelium. It does this in four concentration-dependent steps:

• pH buffering. SNAC raises the local stomach pH from ~1–2 up to ~5, which inactivates pepsin so the enzyme cannot cleave the drug.
• Monomerization. SNAC weakens the hydrophobic forces that make peptides clump. Only single molecules can cross a cell wall.
• Membrane fluidization. SNAC tucks itself into the lipid bilayer of stomach-lining cells, increasing membrane fluidity by ~43% at therapeutic concentrations and creating transient soft spots.
• Reversible release. The SNAC–peptide interaction is non-covalent. Once the peptide is in the bloodstream, SNAC lets go and is cleared by the kidneys.

Why "1% bioavailability" is the headline

Oral semaglutide bioavailability is 0.4–1%. Read that line in a textbook and it sounds like a failure. In context it is the headline. Semaglutide binds the GLP-1 receptor at picomolar concentrations — meaning the dose that makes it through is therapeutically active — and the half-life is about a week, so dosing accumulates and smooths out the variability in stomach conditions.

The catch is patient adherence. For SNAC to work, the pill must be taken on an empty stomach with no more than 120 mL of plain water, and you have to wait at least 30 minutes before food, drink, or any other medication. Break those rules and SNAC dilutes below its active threshold, gastric transit speeds up, and the dose is effectively lost.

A 1% delivery rate is fine when the molecule binds at picomolar concentrations and lasts a week.

The downstream effect

Oral semaglutide is the first FDA-approved oral peptide using a permeation enhancer. The clinical and regulatory template it established now sits underneath every oral biologic in development — including oral GLP-1/GIP combinations, oral glucagon antagonists, and an early wave of oral cytokines. The next generation of devices (RaniPill-style swallowable microneedle capsules, transdermal patches with sustained release) is racing the SNAC approach to second-generation oral delivery.